What this means
This is a trial that is still signing up people, so no results are reported yet. It will test whether exercise and a supplement called NR can improve muscle and fitness over 16 weeks.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 10–30
- Where
- 3 sites, including California, Pennsylvania, Tennessee
The science
- Registered title
- Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors
- Trial ID
- NCT05194397 ↗
- Phase
- PHASE 2
- Study type
- interventional
- Conditions
- Lymphoblastic Leukemia, Cancer Survivors, Aplastic Anemia, Myelodysplastic Syndromes, Myeloid Leukemia
- What is tested
- Nicotinamide Riboside, Placebo, Exercise Intervention
- Sponsor
- Children's Hospital of Philadelphia
- Ages
- 10 Years to 30 Years
- Dates
- First posted Jan 18, 2022 · updated Dec 4, 2025
Registry summary
This will be a randomized, placebo-controlled trial with a 2x2 factorial design testing the effects of an NAD+ precursor (NR) and exercise on skeletal muscle quality and VO2max in AYA HCT survivors.
The primary outcome is the change in muscle strength (isometric knee extension) from baseline to 16 weeks. Key secondary outcomes are the change in muscle strength (ankle plantarflexion) from baseline to 16 weeks, the change in grip strength from baseline to 16 weeks, the change in lower extremity muscle mass from baseline to 16 weeks, the change in muscle OXPHOS capacity from baseline to 16 weeks, and the change in aerobic capacity (VO2 max) from baseline to 16 weeks.
Sites (3)
- City of Hope Medical Center, Duarte, California, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- St. Jude Children's Research Hospital, Memphis, Tennessee, United States